Ephicacy Corporation Limited

Ephicacy Corporation Limited specializes in data analytics services tailored for the clinical industry, focusing on enhancing clinical trial efficiency and supporting pharmaceutical and biotech firms with comprehensive data solutions. Founded in 2005 in Woodbridge, US, Ephicacy Corporation Limited operates as a Contract Research Organization (CRO) dedicated to data analytics in clinical research. The firm has completed one deal, with the most recent one occurring on July 21, 2022. The company has not undergone any reported pivots or changes in business strategy.

Ephicacy Consulting Group provides specialized data analytics services within the clinical industry, primarily functioning as a data analytics Contract Research Organization (CRO). Their offerings include high-quality statistical programming, data management, biostatistics, and real-world evidence services that facilitate both pre-approval and post-approval analytics. They cater to a diverse clientele, including leading pharmaceutical companies and emerging biotech firms, with tailored solutions designed to optimize the clinical trial process and expedite the market entry of innovative therapies across North America, Europe, and Asia. Ephicacy Consulting Group generates revenue through structured transactions with clients, predominantly through B2B partnerships.

They utilize flexible staffing models alongside traditional project-based arrangements, enabling a diversified client approach. Revenue streams include ongoing subscriptions for data analytics support and fixed fees for specific projects, with agreed pricing for critical services such as statistical programming and biostatistics. Their focus on quality and efficiency establishes them as a reliable partner in the clinical trial sector. Following the investment from Great Point Partners in July 2022, the funds will be utilized by Ephicacy Corporation Limited to enhance its clinical services and strengthen business operations.

Although specific upcoming products have not been disclosed, the investment indicates a strategic move towards improving operational capabilities. The company is targeting expansion into new markets, although specific regions have not been mentioned. This growth strategy is integral to Ephicacy's long-term development and operational effectiveness.